The Phase III clinical trial of ImClone Systems' Erbitux found that, when used alone, the drug extended the lives of patients with metastatic colon cancer who have stopped responding to conventional chemotherapy. "These data demonstrate that Erbitux may provide certain colorectal cancer patients with additional time even when other available treatment options have failed," one oncologist said.

Full Story:
Forbes, Bloomberg

Related Summaries